Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.
As of close of business last night, Biolife Solutions Inc’s stock clocked out at $15.86, up 4.76% from its previous closing price of $15.14. In other words, the price has increased by $4.76 from its previous closing price. On the day, 0.6 million shares were traded. BLFS stock price reached its highest trading level at $16.02 during the session, while it also had its lowest trading level at $14.85.
Ratios:
To gain a deeper understanding of BLFS’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.83 and its Current Ratio is at 2.86. In the meantime, Its Debt-to-Equity ratio is 0.13 whereas as Long-Term Debt/Eq ratio is at 0.10.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Jefferies on April 04, 2024, initiated with a Buy rating and assigned the stock a target price of $22.
On July 11, 2023, Craig Hallum started tracking the stock assigning a Buy rating and target price of $29.
Oppenheimer Upgraded its Perform to Outperform on April 25, 2022, while the target price for the stock was maintained at $28.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Apr 15 ’24 when Berard Todd sold 10,000 shares for $15.67 per share. The transaction valued at 156,700 led to the insider holds 129,644 shares of the business.
Aebersold Sarah sold 4,000 shares of BLFS for $70,600 on Apr 01 ’24. The Chief Human Resources Officer now owns 65,843 shares after completing the transaction at $17.65 per share. On Mar 27 ’24, another insider, Berard Todd, who serves as the Chief Marketing Officer of the company, sold 515 shares for $17.99 each. As a result, the insider received 9,265 and left with 139,644 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BLFS now has a Market Capitalization of 718457984 and an Enterprise Value of 709454016. For the stock, the TTM Price-to-Sale (P/S) ratio is 5.01 while its Price-to-Book (P/B) ratio in mrq is 2.12. Its current Enterprise Value per Revenue stands at 4.952 whereas that against EBITDA is -15.683.
Stock Price History:
Over the past 52 weeks, BLFS has reached a high of $24.50, while it has fallen to a 52-week low of $8.92. The 50-Day Moving Average of the stock is -9.63%, while the 200-Day Moving Average is calculated to be 2.86%.
Shares Statistics:
It appears that BLFS traded 369.57K shares on average per day over the past three months and 312090 shares per day over the past ten days. A total of 45.17M shares are outstanding, with a floating share count of 43.15M. Insiders hold about 4.74% of the company’s shares, while institutions hold 100.71% stake in the company. Shares short for BLFS as of 1711584000 were 3198628 with a Short Ratio of 8.65, compared to 1709164800 on 3278551. Therefore, it implies a Short% of Shares Outstanding of 3198628 and a Short% of Float of 10.6800005.
Earnings Estimates
The current rating of Biolife Solutions Inc (BLFS) reflects the combined expertise of BioLife Solutions, Inc. analysts actively engaged in assessing its market performance.The consensus estimate for the next quarter is $3.27, with high estimates of $8.02 and low estimates of $35.45.
Analysts are recommending an EPS of between $Financial Services and $Real Estate for the fiscal current year, implying an average EPS of $Consumer Defensive.
